Provided are a stable FGF21 mutant, fusion polypeptide and conjugate comprising the mutant, as well as a use of the mutant in the preparation of medicaments for treating metabolic disorders. The mutant comprises only one amino acid substitution at position 59 or 71.
申请公布号
WO2015103782(A1)
申请公布日期
2015.07.16
申请号
WO2014CN70506
申请日期
2014.01.13
申请人
WENZHOU MEDICAL COLLEGE BIOLOGICAL PHARMACEUTICALS AND NATURE PRODUCTS LTD., CO;HANGZHOU RECEPTZ BIOTECH, CO., LTD.;HUANG, ZHIFENG
